Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia

Next Previous
Search
Trial Profile

A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbidopa (Primary) ; Droxidopa (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Chelsea Therapeutics

Most Recent Events

  • 22 Dec 2011 Top-line results have been presented in a Chelsea Therapeutics media release.
  • 03 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 03 Aug 2011 Planned End Date changed from 1 Dec 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top